Vigil Neuroscience Inc (VIGL)

$8.05 0.00 (N/A)
Market Cap 383.88M
Revenue (ttm) 0.00
Net Income (ttm) -84.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,506,700
Avg Vol 2,021,136
Day's Range N/A - N/A
Shares Out 47.69M
Stochastic %K 40%
Beta 3.33
Analysts Hold
Price Target $8.00

Company Profile

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids a...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 254 4445
Address:
100 Forge Road, Suite 700 Watertown, Watertown, United States
d_risk
d_risk Aug. 5 at 1:17 PM
$VIGL - Vigil Neuroscience Inc. Common Stock - 10Q - Updated Risk Factors VIGL’s 2025 risks center on merger uncertainties, intensified clinical and regulatory hurdles for VG-3927, expanded IP and patent challenges, heightened cybersecurity threats, reliance on third parties, competitive pressures, stockholder control risks, and ongoing financial losses with no assurance of profitability. #Biotechnology #Cybersecurity #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/VIGL/10-Q/2025-08-05
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Aug. 5 at 7:42 AM
$VIGL Vigil Neuroscience (VIGL) stock is halted because of a pending merger with Sanofi. The merger was approved by shareholders and the stock was halted in anticipation of the deal closing. The final day of trading for VIGL was August 4, 2025, and the stock will be suspended effective August 6, 2025.
0 · Reply
Mergerbrief
Mergerbrief Aug. 4 at 12:07 PM
$VIGL / $SNY - Shareholder Vote $VIGL MergerBrief.com For Full Schedule
0 · Reply
theoptionsplug
theoptionsplug Jul. 21 at 5:25 AM
The most overbought stocks according to their 14-day RSI: Monogram Technologies $MGRM, Cogent Biosciences Inc $COGT, and Vigil Neuroscience $VIGL The most oversold stocks according to their 14-day RSI: Intapp $INTA and NextNRG $NXXT
0 · Reply
GOLDENSAFEBETS
GOLDENSAFEBETS Jul. 19 at 2:47 PM
$VIGL 🐂🧃💎
0 · Reply
Norbert90
Norbert90 Jul. 9 at 3:22 PM
$VIGL No more free CVRs.
1 · Reply
BioTechHealthX
BioTechHealthX Jul. 6 at 5:30 PM
$VIGL Learn why Sanofi’s $600M acquisition of Vigil Neuroscience could signal a shift in Alzheimer’s treatment. VIGL may still have room to run. https://biotechhealthx.com/biotech-news/vigil-neuroscience-vigl-the-tiny-biotech-sanofi-just-bet-600m-on/
1 · Reply
junglezoo
junglezoo Jul. 6 at 3:41 PM
$NKGN $VIGL
0 · Reply
Norbert90
Norbert90 Jul. 2 at 1:23 PM
$VIGL Third and final quarter. Any updates on timeline for the deal closing?
1 · Reply
Joe_088
Joe_088 Jul. 2 at 1:21 PM
$DWTX $VIGL $WINT 3 stock was 💎💎💎
0 · Reply
Latest News on VIGL
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

Jul 14, 2025, 4:06 PM EDT - 5 weeks ago

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

SNY

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

Jun 4, 2025, 7:00 AM EDT - 2 months ago

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

Sanofi to Buy Vigil Neuroscience for About $470 Million

May 21, 2025, 7:59 PM EDT - 3 months ago

Sanofi to Buy Vigil Neuroscience for About $470 Million

SNY

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

May 21, 2025, 7:30 PM EDT - 3 months ago

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

SNY

Sanofi to acquire Vigil Neuroscience in $470 million deal

May 21, 2025, 7:29 PM EDT - 3 months ago

Sanofi to acquire Vigil Neuroscience in $470 million deal

SNY

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline

May 21, 2025, 7:15 PM EDT - 3 months ago

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline

SNY

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

May 7, 2025, 7:00 AM EDT - 3 months ago

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Apr 2, 2025, 7:00 AM EDT - 5 months ago

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Mar 13, 2025, 7:00 AM EDT - 5 months ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Mar 11, 2025, 7:00 AM EDT - 5 months ago

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 30, 2025, 7:00 AM EST - 7 months ago

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Jan 23, 2025, 11:33 AM EST - 7 months ago

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease

Jan 23, 2025, 7:00 AM EST - 7 months ago

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Jan 8, 2025, 4:05 PM EST - 8 months ago

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Sep 16, 2024, 4:05 PM EDT - 1 year ago

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Vigil Neuroscience to Present at Upcoming September Investor Conferences

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience to Present at Upcoming September Investor Conferences

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Jul 18, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

Jun 27, 2024, 2:00 AM EDT - 1 year ago

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

Jun 26, 2024, 1:00 AM EDT - 1 year ago

Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

Vigil Neuroscience to Present in Upcoming June Investor Conferences

May 30, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present in Upcoming June Investor Conferences

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

May 8, 2024, 7:40 AM EDT - 1 year ago

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:05 PM EDT - 1 year ago

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 26, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Mar 20, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Mar 13, 2024, 7:05 AM EDT - 1 year ago

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Mar 12, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Mar 6, 2024, 4:25 PM EST - 1 year ago

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Feb 29, 2024, 4:05 PM EST - 1 year ago

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

Feb 7, 2024, 4:05 PM EST - 1 year ago

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Jan 3, 2024, 4:30 PM EST - 1 year ago

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

Nov 22, 2023, 4:05 PM EST - 1 year ago

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway

Nov 20, 2023, 7:34 PM EST - 1 year ago

Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

Nov 16, 2023, 4:05 PM EST - 1 year ago

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 7:05 AM EST - 1 year ago

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease

Oct 17, 2023, 7:05 AM EDT - 2 years ago

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Oct 5, 2023, 4:01 PM EDT - 2 years ago

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

Sep 26, 2023, 7:05 AM EDT - 2 years ago

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

Vigil Neuroscience: Interesting Early Data, Wait For Phase 2

Sep 18, 2023, 2:38 PM EDT - 2 years ago

Vigil Neuroscience: Interesting Early Data, Wait For Phase 2

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

Sep 11, 2023, 12:00 PM EDT - 2 years ago

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

Sep 8, 2023, 4:05 PM EDT - 2 years ago

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference

Sep 8, 2023, 7:05 AM EDT - 2 years ago

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference

d_risk
d_risk Aug. 5 at 1:17 PM
$VIGL - Vigil Neuroscience Inc. Common Stock - 10Q - Updated Risk Factors VIGL’s 2025 risks center on merger uncertainties, intensified clinical and regulatory hurdles for VG-3927, expanded IP and patent challenges, heightened cybersecurity threats, reliance on third parties, competitive pressures, stockholder control risks, and ongoing financial losses with no assurance of profitability. #Biotechnology #Cybersecurity #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/VIGL/10-Q/2025-08-05
0 · Reply
FreeBeerTomorrow
FreeBeerTomorrow Aug. 5 at 7:42 AM
$VIGL Vigil Neuroscience (VIGL) stock is halted because of a pending merger with Sanofi. The merger was approved by shareholders and the stock was halted in anticipation of the deal closing. The final day of trading for VIGL was August 4, 2025, and the stock will be suspended effective August 6, 2025.
0 · Reply
Mergerbrief
Mergerbrief Aug. 4 at 12:07 PM
$VIGL / $SNY - Shareholder Vote $VIGL MergerBrief.com For Full Schedule
0 · Reply
theoptionsplug
theoptionsplug Jul. 21 at 5:25 AM
The most overbought stocks according to their 14-day RSI: Monogram Technologies $MGRM, Cogent Biosciences Inc $COGT, and Vigil Neuroscience $VIGL The most oversold stocks according to their 14-day RSI: Intapp $INTA and NextNRG $NXXT
0 · Reply
GOLDENSAFEBETS
GOLDENSAFEBETS Jul. 19 at 2:47 PM
$VIGL 🐂🧃💎
0 · Reply
Norbert90
Norbert90 Jul. 9 at 3:22 PM
$VIGL No more free CVRs.
1 · Reply
BioTechHealthX
BioTechHealthX Jul. 6 at 5:30 PM
$VIGL Learn why Sanofi’s $600M acquisition of Vigil Neuroscience could signal a shift in Alzheimer’s treatment. VIGL may still have room to run. https://biotechhealthx.com/biotech-news/vigil-neuroscience-vigl-the-tiny-biotech-sanofi-just-bet-600m-on/
1 · Reply
junglezoo
junglezoo Jul. 6 at 3:41 PM
$NKGN $VIGL
0 · Reply
Norbert90
Norbert90 Jul. 2 at 1:23 PM
$VIGL Third and final quarter. Any updates on timeline for the deal closing?
1 · Reply
Joe_088
Joe_088 Jul. 2 at 1:21 PM
$DWTX $VIGL $WINT 3 stock was 💎💎💎
0 · Reply
Ridiculous78
Ridiculous78 Jun. 26 at 10:24 PM
$VIGL Made some good money here. You will be missed 👍🏼
0 · Reply
Stocks4thought
Stocks4thought Jun. 26 at 11:10 AM
$TCRX Its another $SGMT OR $VIGL - they drive them deep and then algo-s build tremendous wealth. Saw it with $SLNO cost basis $3.42. GO Figure or Go f the traders.
0 · Reply
BinaryLogic
BinaryLogic Jun. 26 at 2:38 AM
$VTYX $RGLS $VIGL
0 · Reply
GreylockSec
GreylockSec Jun. 23 at 11:08 PM
$TPST ....A nice little buyout from this past May from Sanofi that sort of went under the radar, yet still brings a bit of fresh hopium into the small-cap biotech world.... ...Sanofi bought only one of two therapies developed by $VIGL Vigil, being its lead, stage-2-ready, Alzheimer's candidate (a TREM-2 protein that shows up on immune cells in the brain, and still remains a mostly uncharted target) for a whopping $470 million in cash (or $8/share) and another $2 worth of CVRs should the therapy progress...A big payout for a Stage-1 (potential) therapy. ....Small, Stage-1 experimental therapy buyouts like this one by big-pharma help to shape the appearance of a rising biotech comeback with such forward-thinking investments already this year. Thank God Brady knows his science.
0 · Reply
Stocks4thought
Stocks4thought Jun. 23 at 1:49 PM
$ANIX $SGMT $VIGL it works https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
0 · Reply
Quantumup
Quantumup Jun. 23 at 12:03 PM
Canaccord Genuity reiterated $VTYX Buy-$14 after Ventyx reported positive results from the Phase lla open-label study for VTX3232 in early Parkinson's disease (PD). $VIGL - $SNY Canaccord Genuity said in its note; "The trial's positive results demonstrated effective inhibition of NLRP3 and suppression of downstream biomarkers. Results from the trial support once-daily dosing. Ventyx plans to initiate a Phase II dose-ranging study for the drug in patients with Parkinson's. We are encouraged by the reported results from the Phase lla trial, and we believe the study results support a potential indication of VTX3232 in additional neurodegenerative diseases. We remain bullish on shares of $VTYX and reiterate our $14 12-month PT."
0 · Reply
LifeisaMeme
LifeisaMeme Jun. 19 at 5:35 PM
$VTYX $RGLS $VIGL What kind of engineering did you study
0 · Reply
BinaryLogic
BinaryLogic Jun. 19 at 3:55 PM
$VTYX $RGLS $VIGL [Again]
0 · Reply
jacksparo
jacksparo Jun. 16 at 11:52 PM
$VERV Big pay day comes for whom the ones hold this one from my email few weeks ago!! Big move AH with buy out news! The second buy out in less than three weeks from Jack emails! Remember $VIGL And now VERV!
1 · Reply
Stocks4thought
Stocks4thought Jun. 16 at 8:03 PM
$ANIX Just like $VIGL $SGMT they rise- I believe stocks are so manipulated to the downside- to enable [positioning for huge gains- follow suit- https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/
1 · Reply
BinaryLogic
BinaryLogic Jun. 14 at 11:59 PM
$VTYX Look at $RGLS and $VIGL, then come to $VTYX and you will see that some investor(s) are consistently and continuously building here, methodically, taking the SP off of Overbought conditions then continuing to climb. Look at the product pipeline here: multiple phase-2/3 candidates across Crohn's, ulcerative colitis, Parkinson's and peridcarditis. Now-look at the financial statements. This Company has more than doubled over the last month and it is still valued under BV! Excellent acquisition target with 3-5X additional upside (IMO). https://ventyxbio.com/pipeline/
1 · Reply
Quantumup
Quantumup Jun. 12 at 7:15 PM
Piper Sandler, on June 9, reiterated $VTYX OW-$21 and said "we remain bullish on $VTYX's robust NLRP3 portfolio and believe these key readouts are de-risked given its straightforward MoA validated by approved IL-1ß agents." $VIGL - $SNY Piper Sandler additionally said in its note to investors:
0 · Reply